

WEST**Freeform Search****Database:**

US Patents Full-Text Database
US Pre-Grant Publication Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Term:

solution same 18

Display: **Documents in Display Format:** **Starting with Number** **Generate:** ☐ Hit List ☒ Hit Count ☐ Side by Side ☐ Image

Search

Clear

Help

Logout

Interrupt

Main Menu

Show 8 Numbers

Edit 8 Numbers

Preferences

Cases

Search History**DATE:** Wednesday, December 10, 2003 [Printable Copy](#) [Create Case](#)

Set Name Query
side by sideHit Count Set Name
result set*DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ*

<u>L11</u>	solution same l8	60	<u>L11</u>
<u>L10</u>	L8 same (polymer same microparticle)	7	<u>L10</u>
<u>L9</u>	L8 same microparticle	12	<u>L9</u>
<u>L8</u>	l5 with l3 with l1	196	<u>L8</u>
<u>L7</u>	L6 same microparticle	9	<u>L7</u>
<u>L6</u>	L5 with l4	127	<u>L6</u>
<u>L5</u>	percent	542850	<u>L5</u>
<u>L4</u>	L3 with l2 with l1	1583	<u>L4</u>
<u>L3</u>	drug or biologically active molecule or macromolecule or DNA or nucleic	421869	<u>L3</u>
<u>L2</u>	weight	2261228	<u>L2</u>

DB=USPT; PLUR=YES; OP=ADJ

<u>L1</u>	microparticle or polymer	405267	<u>L1</u>
-----------	--------------------------	--------	-----------

END OF SEARCH HISTORY

WEST

Generate Collection

Print

L3: Entry 9 of 55

File: USPT

Nov 5, 2002

DOCUMENT-IDENTIFIER: US 6475779 B2

**** See image for Certificate of Correction ****

TITLE: Polymeric gene delivery

CLAIMS:

6. The preparation of microparticles according to claim 1 wherein approximately 0.1 -90% by weight of the naked DNA is loaded into the polymeric matrix.

WEST

Generate Collection

Print

L3: Entry 20 of 55

File: USPT

Aug 14, 2001

DOCUMENT-IDENTIFIER: US 6274175 B1
TITLE: Prolonged release of GM-CSF

Detailed Description Text (41):

Loading is dependent on the disorder to be treated as well as the time period over which the GM-CSF is to be released. Lower dosages are required for use as a vaccine adjuvant, in the range of 0.001 to 0.1%. Microparticles for treatment of a severe infection would typically be delivered in microparticles with 2% by weight drug loading.

WEST

Generate Collection

Print

L3: Entry 21 of 55

File: USPT

Jul 31, 2001

DOCUMENT-IDENTIFIER: US 6268053 B1

TITLE: Macromolecular microparticles and methods of production and use

Brief Summary Text (15):

The microparticles are composed of polymer and macromolecules. At least 40% and less than 100% of the final weight of each microparticle is composed of macromolecules. Preferably, the concentration of polymer is less than 30% by weight of the total microparticle weight.

Brief Summary Text (25):

It is a further object of the present invention to provide a process for making microparticles in which the macromolecule concentration is at least 40% by weight.

Detailed Description Text (3):

The macromolecule or combination of macromolecules compose at least 40% and less than 100% by weight of the final weight of each microparticle. Preferably, the polymer concentration in the microparticle is greater than 0% and less than or equal to 30% by weight. The types of macromolecules forming the microparticles include, but are not limited to, proteins, peptides, carbohydrates, conjugates, nucleic acids, viruses, or mixtures thereof.

CLAIMS:

1. A microparticle comprising macromolecule and polymer, wherein the concentration of macromolecule in the microparticle is at least 40% and less than 100% by weight.
2. A microparticle comprising a macromolecule and a polymer, wherein said macromolecule is a hormone, and said polymer is a water soluble, linear or branched high molecular weight polymer capable of removing water from the macromolecule.

WEST

Generate Collection

Print

L7: Entry 7 of 9

File: USPT

May 22, 1990

DOCUMENT-IDENTIFIER: US 4927687 A

TITLE: Sustained release transdermal drug delivery composition

Brief Summary Text (37):

The reservoir comprises a dermatologically-acceptable, generally viscous liquid base material, the viscosity should be sufficiently high to suspend the microparticles therein and to prevent leakage or excessive flow through the membrane pores, but low enough to permit the function of the thin film on the skin. A plurality of solid microparticles or microspheres are generally uniformly dispersed and suspended in the liquid base material within the reservoir. The microparticles include an effective therapeutic amount of an active drug ingredient or a combination thereof, such as a contraceptive steroid, like levonorgestrel or estradiol or a combination thereof for transdermal delivery for a particular therapeutic purpose such as contraception. The drug is present in an effective therapeutic amount within the microparticles suspended in the reservoir with the microparticles generally designed to provide for a zero order release of the active drug material. Preferably, the microparticles are composed of an admixture of a polymer with the active drug ingredient in the microparticles varying as desired, but generally from about 0.1 to 30 percent by weight, for example, 1 to 20 percent and wherein the microparticle has a thin polymer wall coating thereon such as a wall coating imparted in a fluid bed coating system or by other means. Typically an adhesive layer is placed about the periphery of the drug delivery system and usually an impermeable material such as a protective peel strip is secured to the open face of the macroporous membrane, which peel strip is to be removed just prior to use.

Brief Summary Text (43):

The microparticles employed in the drug delivery system generally comprise solid microparticles wherein the core of the particle contains an admixture of a polymer together with one or more of the drugs which are to be delivered by the microparticles, the active ingredient in the core may comprise a varying amount and range for example from 5 to 95 percent by weight, such as 20 to 80 percent by weight with the remainder made up a core polymer material. The amount of microparticles in the base material may vary and range from 5 to 70 percent, e.g. 10-30 percent by volume of the reservoir material. The microparticle comprises and has a wall thickness of generally the same or similar polymer as the core material. The core material, of course, may have other additives, such as binders, adhesives, fillers and the like. The microparticles may have a wall coating produced by coating of the solution in a fluidized bed to provide a generally uniform wall thickness.

Detailed Description Text (5):

FIG. 3(a) illustrates an in vitro sustained release of levonorgestrel from a microparticle wherein the drug comprises about 10 percent of the microparticles and the biodegradable polymer of polylactide comprises about 90 percent by weight of the core material and wherein the wall thickness of the microparticle ranges from about 3 to 8 microns and is composed of the polylactide polymer.

CLAIMS:

11. The composition of claim 1 wherein the drug comprises from about 0.1 to 30 percent by weight of the microparticle.

WEST

Generate Collection

Print

L10: Entry 1 of 7

File: USPT

Jul 17, 2001

DOCUMENT-IDENTIFIER: US 6262127 B1

**** See image for Certificate of Correction ****

TITLE: Polymeric matrices and their uses in pharmaceutical compositions

Detailed Description Text (81):

Examples of drug loadings for the preferred compound octreotide are for acromegaly, in a parenteral liquid depot formulation having microparticles which contain the peptide in an amount from at least 0.1 preferably 0.5 to 20 percent by weight relative to the (co)-polymer matrix, preferably 2.0 to 10, especially 3 to 6% of weight. The total dose of octreotide is 20 to 30 mg in acromegaly and up to 100 to 200 mg in breast cancer, e.g. for 1 month of treatment.